Up­dat­ed: A GPCR start­up out of France and Cana­da scores its Se­ries A af­ter 14 years of wheel­ing and deal­ing

Hav­ing al­ready nailed down mul­ti­ple li­cens­ing and col­lab­o­ra­tion deals with Big Phar­ma gi­ants like Bris­tol My­ers Squibb and Pfiz­er, a France- and Que­bec-based GPCR biotech now has its first VC fi­nanc­ing round un­der its belt.

The I/O fo­cused biotech Do­main Ther­a­peu­tics closed a Se­ries A worth $42 mil­lion, the com­pa­ny an­nounced Tues­day — which will last two years, ac­cord­ing to CEO Pas­cal Neuville. Do­main had pre­vi­ous­ly built nu­mer­ous part­ner­ships with dif­fer­ent phar­ma com­pa­nies since its found­ing in 2008, such as Mer­ck KGaA, Take­da and Boehringer In­gel­heim.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER